Byetta scrips up this week to 58k
AMLN continues to make steady progress in Byetta sales, setting a new weekly record of 58269 scrips for Byetta. Check out the sales data:
http://members.cox.net/mystock/Amylin.htm
As the scrip #'s go up, so must the stock... and remember, we still have all of Europe to service, then there's Byetta LAR, nasal delivery, and weight loss claims, and the list goes on!
Byetta works better than Lantus
which means that more people will be buying the stuff!
from:
http://biz.yahoo.com/ap/070921/amyli...over.html?.v=1
AP
Amylin Shares Rise on Study Claim
Friday September 21, 12:12 pm ET
Amylin Pharmaceuticals Shares Rise on Study Claim Comparing Byetta With Competitor
NEW YORK (AP) -- Shares of Amylin Pharmaceuticals Inc. jumped Friday after the company and its partner Eli Lilly & Co. cited a study claiming its diabetes drug Byetta is more effective than Sanofi-Aventis' Lantus.
San Diego-based Amylin and Indianapolis-based Eli Lilly said a one-year study showed that Byetta was more effective in treating type 2 diabetes and patients lost weight. The companies said patients taking Lantus gained weight. The results were presented at the 43rd Annual Meeting of the European Association for the Study of Diabetes in Amsterdam. It involved 69 people.Shares of Amylin rose $1.64, or 3.4 percent, to $49.68 in midday trading. The stock has traded between $35.55 and $53.25 over the last 52 weeks. Shares of Eli Lilly rose 77 cents to $57.85 and shares of Paris-based Sanofi-Aventis fell 40 cents to $42.70.
"We think these results bode well for the upcoming Byetta monotherapy results--expected in the fourth quarter--in early-stage patients as this study clearly demonstrates Byetta's efficacy in earlier-stage patients," wrote FBR Research analyst Jim Reddoch, in a note to investors.
He said positive study results from the monotherapy results could add an additional 8 million eligible patients to Byetta's current total of about 5 million. He reaffirmed a "Outperform" rating on the stock and $62 price target.
Symlin was approved by FDA in a new package this week.
It wasn't in the news, but it's posted on the FDA site... AMLN received an approval for a package change for Symlin.
from:
http://www.fda.gov/cder/whatsnew.htm
September 27, 2007
- New and Generic Drug Approvals
- Abilify (aripiprazole) Intramuscular Injection, Otsuka, Labeling Revision
- Abilify (aripiprazole) DISCMELT, Otsuka, Labeling Revision
- Abilify (aripiprazole) Oral Solution, Otsuka, Labeling Revision
- Abilify (aripiprazole) Tablets, Otsuka, Labeling Revision
- Albuterol Sulfate Inhalation Solution, Watson Labs, Approval
- Gabapentin Capsules, Hikma Pharma, Approval
- KALETRA (lopinavir/ritonavir) Tablets, Abbott Labs, Labeling Revision
- KALETRA (lopinavir/ritonavir) Oral Solution, Abbott Labs, Labeling Revision
- Methimazole Tablets, Caraco Pharma, Approval
- Symlin (pramlintide acetate) Injection, Amylin Pharma, Package Change
- Zebeta (bisoprolol fumarate) Tablets, Duramed Pharma, Labeling Revision
- Ziac (bisoprolol fumarate and hydrochlorothiazide) Tablets, Duramed Pharma, Labeling Revision
- PDUFA Information: Notice to Applicants Submitting NDAs/BLAs to CDER/CBER for Fiscal Year 2008
Reposting from the POTW thread
This post really belongs here:
Quote:
Originally Posted by New-born baby http://www.mrmarketishuge.com/images...s/viewpost.gif
Jiesen,
Whatever happened to AMLN? Looking short to $36 on this once high flier.
AMLN is getting taken down hard on good news. Just like it did when Byetta and Symlin were approved. Stock tanked from $25 to 15 (or something like that) and it provided me a great entry at $20.
http://biz.yahoo.com/prnews/071031/law097.html?.v=101
Now it's the same thing, imo. Byetta LAR (Long-acting release version) clinical data just came in, says it's better than Byetta, and so someone is dropping the price... perhaps trying to exit a big short, or buy a big piece of the company on the cheap.
AMLN is a bargain at $41, but that doesn't mean it won't go to $30 before taking off again.
Sales will pick up with Byetta LAR, but it will take a couple of years. Approval is still not guaranteed, but it should happen in 2009. With once per week injections, instead of twice daily, there will be little excuse left for doctors not to prescribe it. Plus, it works better at controlling glucose levels! Many people using Byetta now are reducing, or even eliminating their need for insulin injections. I don't think the competing drugs (Januvia) are able to do the same.
The reason Januvia is outselling Byetta now is mostly the inconvenience of the injections vs the convenience of Januvia's pill form, but also because of the weight of MRK's marketing machine. When people wise up and realize which drug actually performs better, the sales will finally reflect it.
I still think AMLN is a great stock to own, and still own my $20 shares. However, LJPC offers a much greater opportunity for weekly triple-digit gains, which is what I'm hoping to get here (one of these days). When positive Riquent results are announced (and they should be someday soon) the stock has the potential to jump from $4 to $40 in a month, week, or even a day. I would hate to be out of LJPC on that day...